Results 91 to 100 of about 1,447,270 (322)

The Nucleus Accumbens: A Comprehensive Review

open access: yesStereotactic and Functional Neurosurgery, 2015
There is increasing interest among functional neurosurgeons in the potential for novel therapies to impact upon diseases beyond movement disorders and pain.
S. Salgado, M. Kaplitt
semanticscholar   +1 more source

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

open access: yesMolecular Oncology, EarlyView.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric   +11 more
wiley   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

open access: yesMolecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane   +16 more
wiley   +1 more source

A new SPS programme [PDF]

open access: yesPoSCPOD2006:016,2006, 2006
A new experiemntal program to study hadron production in hadron-nucleus and nucleus-nucleus collisions at the CERN SPS has been recently proposed by the NA49-future collaboration. The physics goals of the program are: (i) search for the critical point of strongly interacting matter and a study of the properties of the onset of deconfinemnt in nucleus ...
arxiv  

Multiplex single‐cell profiling of putative cancer stem cell markers ALDH1, SOX9, SOX2, CD44, CD133 and CD15 in endometrial cancer

open access: yesMolecular Oncology, EarlyView.
Cancer stem cells are associated with aggressive disease, but a deep characterization of such markers is lacking in endometrial cancer. This study uses imaging mass cytometry to explore putative cancer stem cell markers in endometrial tumors and corresponding organoid models.
Hilde E. Lien   +7 more
wiley   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

open access: yesMolecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park   +6 more
wiley   +1 more source

New features in DPMJET version II.5 [PDF]

open access: yesarXiv, 1999
DPMJET is a Monte Carlo model for sampling of hadron-hadron, hadron-nucleus, nucleus-nucleus and neutrino-nucleus interactions at accelerator and Cosmic Ray energies according to the two-component Dual Parton Model. Here we describe new features in version DPMJET-II.5: Implementation of new DPM diagrams for an improved description of baryon stopping in
arxiv  

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

open access: yesMolecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy